Melbourne, Australia and New York-based Mesoblast Limited announced that in a study of COVID-19 patients with moderate to severe acute respiratory distress syndrome, there was 83 percent survival with two intravenous infusions of the company’s experimental allogeneic mesenchymal stem cell candidate Ryoncil (remestemcel-L).
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.
Orchard Therapeutics secured an exclusive license for an ex vivo autologous hematopoietic stem cell gene therapy program for the treatment of MPS-I developed by SR-Tiget.
Orchard Therapeutics announced positive results from a two-year follow up of a stem cell gene therapy for severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID).
Shares of Belgium-based TiGenix NV shot up after Japan’s Takeda Pharmaceutical opted to acquire the company for $630 million.
The FDA will fast track the review of Australian drug developer Mesoblast Ltd.’s cell therapy treatment for heart failure patients under a new designation rolled out in December 2016.
Canada’s Aeterna Zentaris Inc. said the U.S. FDA approved its oral test to diagnose adult growth hormone deficiency.
The U.S. FDA is stepping up efforts to better regulate an emerging field of medicine that holds significant promise for curing some of the most troubling diseases by using the body’s own cells.
Japan-based Astellas Pharma is setting up a new facility in Cambridge, Mass. which is in line with the company’s 2016 strategic focus on innovation and enhancing its capabilities in developing dynamic new treatments to address unmet medical needs.
More than 300 companies are marketing unapproved stem cell procedures at more than 500 clinics in the U.S.